๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin

โœ Scribed by Howard W. Bruckner; Carmel J. Cohen; Judith D. Goldberg; Bernard Kabakow; Robert C. Wallach; Gunter Deppe; Ezra M. Greenspan; Saul B. Gusberg; James F. Holland

Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
671 KB
Volume
47
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Combination chemotherapy with adriamycin
Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma
โœ Leroy M. Parker; C. Thomas Griffiths; Ronald A. Yankee; George P. Canellos; Rebe ๐Ÿ“‚ Article ๐Ÿ“… 1980 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 585 KB

Combination chemotherapy with Adriamycin-cyclophosphamide was employed after surgical treatment in 60 women with Stage 111-IV ovarian adenocarcinoma. Of 53 evaluable patients, objective response was noted in 34 of 41 (83%) without prior cytotoxic therapy but in only two of 12 (17%) who had failed a

Chemotherapy for advanced head and neck
Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen
โœ Edward T. Creagan; Thomas R. Fleming; John H. Edmonson; James N. Ingle; John E. ๐Ÿ“‚ Article ๐Ÿ“… 1981 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 294 KB ๐Ÿ‘ 3 views

Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m2, day 1; cyclophosphamide, 400 mg/m2, day 3; and cis-diamminedichloroplatinum, 20 mg/m2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0112 squamous cell carcinomas; 112 ad